Evidence map›Paper›PMID 40064654›Full record

ArticleCardiovascular and interventional radiology2025

Increased Voxel-Based Y90 Radioembolization Dose to Hepatocellular Carcinoma Improves Imaging Response.

Shanmukha Srinivas, Kurt Pianka, Helena D Rockwell, Akhilesh Yeluru, Joy Liau, Ashwin Ganesh, Jeet Minocha, Cairine McNamee, Steven C Rose, Kathryn Fowler and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Effects of dose heterogeneity on response and toxicity afterEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. MRI radiomics andBMC cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shanmukha SrinivasDepartment of Radiology, University of California, Los Angeles, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. shanmukha@ucla.edu.ORCID http://orcid.org/0000-0002-8556-4563
Kurt PiankaDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Helena D RockwellDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Akhilesh YeluruDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Joy LiauDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Ashwin GaneshDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Jeet MinochaDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Cairine McNameeDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Steven C RoseDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Kathryn FowlerDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA.
Zachary T BermanDepartment of Radiology, University of California, San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA, 92093, USA. zberman@health.ucsd.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the relationship between radioembolization tumor dose and imaging response for hepatocellular carcinoma (HCC) treated with radioembolization. MATERIALS AND

methodsRetrospective single-institution evaluation of treatment-naïve patients with HCC who underwent TARE between November 2017 and September 2020. Dose-volume histograms (DVHs) were calculated from post 90Y single-photon emission computed tomography. Cross-sectional imaging was obtained at 3 months after radioembolization and evaluated by three blinded abdominal radiologists.

resultsForty-one patients underwent radioembolization who met the inclusion criteria. Median age was 67 years (range 41-84); 11 were female. At 3 months, 23/41 (56%) had complete response (CR), 9/41 (22%) had partial response (PR), and 8/41 (20%) had stable disease (SD) by mRECIST criteria. DVH analysis demonstrated that increased dose to different tumor volumes was predictive of a complete imaging response at 3 months (p < 0.05 for all). Receiver operating characteristic (ROC) analysis demonstrated a dose threshold of 687 Gy to 95% of the tumor volume resulted in the highest area under curve (AUC) at 0.86 (CI 0.73-0.95) and a positive predictive value (PPV) of 82% to predict complete response by mRECIST criteria.

conclusionVoxel-based dosimetry demonstrates that several dose thresholds are predictive of a complete imaging response by mRECIST criteria. A threshold dose of 687 Gy to at least 95% of the tumor volume led to the highest accuracy in predicting complete response by mRECIST criteria. LEVEL OF EVIDENCE: Level 3, Cohort Study.

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsYttrium RadioisotopesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiotherapy DosageRetrospective StudiesTomography, Emission-Computed, Single-PhotonTreatment OutcomeYttrium-90Yttrium RadioisotopesHepatocellular carcinomaTransarterial radioembolizationVoxel-based dosimetry

Identifiers

PMID40064654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.